July 24th 2025
The addition of retifanlimab to chemotherapy increased progression-free survival in patients with advanced squamous cell carcinoma of the anal canal.
9th Annual School of Nursing Oncology™
August 9, 2025
Register Now!
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
PER's Satellite Symposia at MHS
August 1-2, 2025
Register Now!
A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and AD...
September 6, 2025
Register Now!
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers
View More
19th Annual New York GU Cancers Congress™
March 13-14, 2026
Register Now!
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes
View More
11th Annual School of Gastrointestinal Oncology® (SOGO®)
April 11, 2026
Register Now!
Addressing Unmet Needs in HER2+ Metastatic BTC
View More
Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer
View More
From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment
View More
Proactive Adverse Event Management for HER2+ BTC Treatments
View More
GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
View More
Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
View More
Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches
View More
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
View More
Zolbetuximab BLA Undergoes Priority Review for CLDN18.2+ Advanced Gastric/Gastroesophageal Cancer
July 11th 2023The FDA has granted priority review to the biologics license application for zolbetuximab as a treatment for patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Encorafenib/Cetuximab/Binimetinib Triplet Safe and Effective in BRAF V600E–Mutant mCRC
May 16th 2023Treatment with encorafenib in combination with cetuximab and binimetinib was active with a manageable safety profile in the first-line setting for patients with BRAF V600E–mutated metastatic colorectal cancer.